Evidence map›Paper›PMID 42720273›Full record

ArticleMolecular omics2026

Baseline cellular state shapes the molecular impact of mutant Kirsten rat sarcoma viral oncogene homologue (KRAS) alleles in reconstituted pancreatic cancer cells.

Yanixa Quiñones-Avilés, Barbora Salovska, Cassandra S Markham, Yi Di, Benjamin E Turk, Yansheng Liu, Mandar Deepak Muzumdar

Abstract read
In one paragraph

Article in Molecular omics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Yanixa Quiñones-AvilésYale Cancer Biology Institute, Yale University, West Haven, CT 06516, United States.ORCID 0000-0002-2238-766X
Barbora SalovskaYale Cancer Biology Institute, Yale University, West Haven, CT 06516, United States.
Cassandra S MarkhamYale Cancer Biology Institute, Yale University, West Haven, CT 06516, United States.
Yi DiYale Cancer Biology Institute, Yale University, West Haven, CT 06516, United States.
Benjamin E TurkCombined Program in the Biological and Biomedical Sciences, Graduate School of Arts and Sciences, Yale University, New Haven, CT 06520, United States.
Yansheng LiuYale Cancer Biology Institute, Yale University, West Haven, CT 06516, United States.ORCID 0000-0002-2626-3912
Mandar Deepak MuzumdarYale Cancer Biology Institute, Yale University, West Haven, CT 06516, United States.ORCID 0000-0001-7424-7223

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 1985 to 2026
$85.0M
Yale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6M
Dietary fatty acids drive pancreatic cancer developmentR01CA276108 · NCI · YALE UNIVERSITY · PI Mandar Deepak Muzumdar · 2023 to 2026
$2.6M
Defining tumor cell and host adaptations in cancer progressionDP2CA248136 · NCI · YALE UNIVERSITY · PI MUZUMDAR, MANDAR DEEPAK · 2019 to 2019
$2.5M
Proteomic and Phosphoproteomic Remodeling Under Genomic ImbalanceR35GM158073 · NIGMS · YALE UNIVERSITY · PI Yansheng Liu · 2025 to 2026
$773k
Differential pathway engagement and the biological consequences of KRAS variants in cancerF31CA265173 · NCI · YALE UNIVERSITY · PI QUINONES AVILES, YANIXA · 2021 to 2023
$140k
American Cancer Society Institutional Research IRG 17-172-57Lustgarten Foundation Therapeutics-Focused Research Program R01-CA276108National Science FoundationNCI Mentored Clinical Scientist Research Career Development K08-CA2080016NCI NIH HHS DP2 CA248136NCI NIH HHS DP2-CA248136NCI NIH HHS F31 CA265173NCI NIH HHS F31-CA265173NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA276108NCI NIH HHS T32 CA193200NIGMS NIH HHS R35 GM158073NIGMS NIH HHS R35-GM158073NIH HHSYale Cancer Biology Training T32-CA193200Yale Cancer Center Internal PilotYale Comprehensive Cancer Center P30-CA016359
6 · The paper itself

Abstract

Kirsten rat sarcoma viral oncogene homologue (KRAS) is mutated in over 90% of pancreatic ductal adenocarcinomas (PDAC), where hotspot alterations in codons 12, 13, and 61 drive tumour initiation and progression. Although distinct biochemical properties have been described for individual KRAS mutants, whether they generate unique allele-specific signalling programmes in PDAC cells remains unresolved. Here, we systematically interrogated the molecular consequences of seven common KRAS mutant variants in reconstituted isogenic, KRAS-deficient PDAC cell lines by integrated transcriptomic, proteomic, and phosphoproteomic profiling. We found that baseline cellular state, rather than allele identity, was the predominant driver of molecular variation. Comparisons with established KRAS reference signatures revealed significant but moderate overlap at the mRNA level and less so at the proteome level. Pathway analyses highlighted the interferon response and mitochondrial translation-related proteins as recurrently altered across mutant alleles, while phosphoproteomic data confirmed robust extracellular signal-regulated kinase 1/2 (ERK1/2) activity and the suppression of dual-specificity tyrosine phosphorylation-regulated kinase substrates by mutant KRAS expression. Importantly, no robust mutant allele-specific molecular programmes were identified in our KRAS-reconstituted cell lines. Together, our study establishes a comprehensive multi-omics resource for KRAS signalling in PDAC and demonstrates that cellular context exerts a stronger influence than allele identity in shaping molecular profiles, with implications for interpreting putative allele-specific signalling dependencies.

Indexed as

Carcinoma, Pancreatic DuctalMutationPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AllelesCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansProteomicsSignal TransductionKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID42720273
PMCPMC13617562

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.